

## Amendments to the Claims

*This listing of claims will replace all prior versions, and listings of claims in the application:*

Claim 1 (previously presented): A pharmaceutical composition comprising an active agent having low water solubility encapsulated in nanoparticles comprising a pharmaceutically acceptable polymer and dispersed in an aqueous formulation base, said aqueous formulation base further comprising polyvinyl alcohol; and wherein said pharmaceutically acceptable polymer, which is resistant to gastric juices and soluble in intestinal juices, is chosen from at least one of polyvinyl acetate phthalate (PVAP) and hydroxypropyl methyl cellulose acetate succinate (HPMCAS); and wherein said pharmaceutical composition is an oral dosage form.

Claim 2 to 31 (cancelled)

Claim 32 (previously presented): A pharmaceutical composition according to claim 1, wherein said active agent is selected from the group consisting of immuno-suppressive agents, non-steroidal anti-inflammatory agents, calcium channel blockers, immunomodulators, and antibiotic agents.

Claim 33 (cancelled)

Claim 34 (previously presented): A pharmaceutical composition according to claim 1, wherein said nanoparticles are nanospheres.

Claim 35 (previously presented): A pharmaceutical composition according to claim 1, wherein said active agent has a water solubility of less than 500 mg/1000 ml.

Claim 36 (previously presented): A pharmaceutical composition according to claim 35, wherein said water solubility is less than 200 mg/1000 ml.

Claim 37 (previously presented): A pharmaceutical composition according to claim 1, wherein said nanoparticles range in a size from about 10 to 1000 nm.

Claim 38 (new): A pharmaceutical composition according to claim 1, wherein said active agent is Boc-Phe[C]-(p-CH<sub>3</sub>O)Phe-(L)-(Phe-morpholin-4-yl)-amide.